Join our community of traders FOR FREE!

  • Learn
  • Improve yourself
  • Get Rewards
Learn More

Key Moments

  • Eli Lilly received U.S. Food and Drug Administration approval for Onswik, a once-weekly basal insulin for adults with type 2 diabetes.
  • The company plans to introduce the Onswik KwikPen to the U.S. market in the coming months.
  • Onswik will be offered in two concentrations: 500 units/mL and 1,000 units/mL.

Regulatory Approval

Eli Lilly has obtained approval from the Food and Drug Administration for Onswik, a once-weekly basal insulin intended for the treatment of adults with type 2 diabetes.

Product Launch and Formulations

According to the company, the Onswik KwikPen is expected to become available in the United States in the coming months. The product will be offered in two distinct concentrations to support dosing flexibility.

ProductFormConcentrations
OnswikKwikPen500 units/mL, 1,000 units/mL
TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover Forex, Price Action and Social Trading.

Related News